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Cytologie smears (CS) were taken from the lateral border of the tongue of HIV-
seropositive patients (HlV-f) {n = 39) and of seronegative controls (HIV-)
(n = 19) and examined by immunocytochemistry (APAAP) and in situ hybridiza-
tion (ISH) (biotinylated DNA probes) for the presence of viral antigens/DNA
of EBV and CMV. While none of the HIV controls showed positive results for
EBV antigen, 61% (APAAP) resp. 79% (ISH) of oral epithelial eells in the group
of HIV-I- patients were EBV-positive. While all CS taken from areas with the
elinical diagnosis of hairy leukoplakia (HL) were EBV positive (APAAP and/
or ISH), the detection of EBV in CS from uninvolved oral mueosa seemed to be
assoeiated with the later development of HL. In the group of HIV-I- patients
the detection rate for CMV was about five times (APAAP) resp. three times
(ISH) higher than in HIV— persons. This non-invasive technique seems to be a
valuable tool to screen for viral antigens/getioms.
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The oral mucosa is an integral part of
the mucocutaneous barrier, whieh pro-
tects against physical, chemieal and bio-
logic noxious stimuli (1). Continuous
viral, bacterial or mycotic stimulation,
modification of the epithelial structure
and local or systemie immunologie al-
terations can lead to disturbances of the
mucosal barrier function, resulting in
elinieal and morphologieal alterations
and dysfunetions of the mucosa (2).
During HIV-infection different oral
manifestations are found (3). Oral
lesions due to herpes viruses are of spe-
cial clinical relevanee, sueh as the EBV
assoeiated hairy leukoplakia (4, 5), or
CMV induced ulcerations (6), and often
show unusual clinical symptoms, local-
ization and/or resistance to therapies.
Since it is often difficult to gain biop-
sies for diagnosis or for therapy moni-
toring, it was the purpose of the present
study to establish a non-invasive tech-
nique for the detection of herpes groitp
viruses.
Material and methods
39 HIV-seropositive patients and 19
HIV-seronegative controls were includ-
ed in this study, HIV seropositivity was
stated by ELISA (DuPont) and con-
firmed by Western blot. Complete his-
tories and examinations of the oral cavi-
ty were done initially and reevaluated
after 8 months. The clinical status was
diagnosed according to the definition of
the Centers for Disease Control (CDC)
(7). Progression of HIV-associated dis-
ease was defined as elinical deteriora-
tion of a patient, resulting in the change
of CDC-group (7). CD4/CD8 ratios
and absolute numbers of T-helper
lymphocytes per |il blood were deter-
mined according to standard methods
(8).
Cytologie smears (CS) were taken
from the lateral border of the tongue
using a metal spatula. After dissolving
in phosphate buffered saline (PBS) and
centrifugation (150 g/5 tnin) trypsine
(0.2%) was added to the cell solution in
order to separate the epithelial cells
from adhering detritus and mucus. The
cell suspension was repeatedly washed
with PBS, centrifugated (100 g/5 miti)
and was filtered using a tefion filter.
Afterwards the superfluous liquid was
removed and the quantity of cells was
controlled in a Neugebauer counting
chatnber (optimal density of cells:
80-100 cells/^tl). After adding 10 nl ace-
tone the cell suspension was irnmediate-
ly distributed onto poly-L-Lysine coat-
ed glass slides, air dried (10 min), fixed
with acetone (5 min), air dried (10 min)
and stored at — 20°C. After fixation (5
min) and air drying (10 min) one slide/
patient was counterstained with hemal-
aun to control the quality of the cell
preparation.
For detection of structural proteins of
EBV (nuclear antigen: NA, virus capsid
antigen: VCA, early antigen: EA) (dilu-
tion: 1:200; Prof. Woif, Munchen) and
CMV (dilution: 1:25; Dakopatts) mo-
noclonal antibodies were applied using
the APAAP technique (9). As pretreat-
ment for this procedure slides were de-
frosted (30 min), fixed with acetone (10
min) and airdried (10 min).
EBV and CMV DNA probes were
obtained from Enzo (Ortho Diagnos-
tics). For in situ hybridization (ISH)
slides were defrosted (30 tnin), air dried
(30 min) and fixed with acetone (10
min). To avoid unspecific reactions with
the streptavidin horseradish peroxidase
complex resp. due to the presenee of
endogenous phosphatase slides were
50 LANGFORD et al.
treated with 0.5% triton (10 min) resp.
H2O2/methanole (5 min). After washing
(aqua dest) and air drying (5 min) the
probe reagent was applied and the slides
were covered with acid-cleaned cover
glasses. Denaturation was performed by
placing the slides in a 92 + 2°C incuba-
tor for 4 min and then immediately plac-
ing the slides in a 37 °C incubator for 20
min to allow for hybridization.
Following hybridization, the eover
glasses were removed, the slides incu-
bated with the post hybridization solu-
tion (1 mM phosphate buffer, 13 mM
NaCl, 50% formamide) and repeatedly
washed (10 mM PBS/5 mM EDTA).
Hybridized biotinylated DNA probes
were detected using an avidin-biotiny-
lated horseradish peroxidase system
(10) with aminoethylcarbazole as chro-
mogen. Finally the cell preparations
were lightly counterstained using Fast
Green (4 min) and coverglassed with
glyeerin jelly.
Using the APAAP technique the spec-
ificity of monoclonal antibodies was test-
ed on Raji cells (negative control for
EBV) and EBV-infeeted Raji and
P3HR1 cells (positive controls for EBV),
on HEL cells (negative eontrol for CMV)
and CMV (strain AD 169) infected HEL
cells (positive control for CMV). For in
situ hybridization the specificity of
probes was tested on Ramos and P3HR1
cells (negative control for EBV) and on
Raji cells and EBV (strain B95-8) in-
fected Ramos and P3HR1 cells (positive
control for EBV), on MRC-5 and HEL
cells (negative control for CMV) and on
CMV infected MRC-5 and HEL cells
(positive control for CMV).
To exelude unspecific reaetions cyto-
logic slides, not incubated with the pri-
mary antibody respectively DNA
probe, were included in all other test
procedures.
The slides were microscopically eval-
uated using a Leitz Orthoplan micro-
scope with a primary magnification of
X 250. All cells of each slide - in average
about 1500 cells - were evaluated. The
slides were scored as being either posi-
tive or negative. Positive cases with less
than five positive cells/slide were classi-
fied as "-I-", those with 5 to 10 positive
cells as "-I--I-" and those with more
than 10 positive cells as " -I- -I- -I-". Posi-
tivity was also designated as nuclear,
cytoplasmic or whole cells. Positive cells
were characterized as cytomegalie, en-
larged or normal sized cells. The mean
Value and standard error of the mean of
the number of positive cells/slide were
determined. To decide whether there
Table 1. Ratio of CD4/CD8 positive cells and absolute number of CD4 positive cells/nl (CD4
b / O (peripheral blood).
Number of patients
CD4/CD8
Average
Standard deviation
Median
Range
CD4 abs/nl
Average
Standard deviation
Median
Range
HIV-I-
39
0.3
0.04
0.3
0.04-1.0
195
39.1
112
7-744
ASY
6
0,7
0.1
0.7
0.3-1.0
532
162
467
214-744
ARC
12
0.4
0.5
0.4
0.2-0.8
350
72.5
316
155-570
AIDS
21
0.1
0.02
0,1
0.04-0.4
96
17.4
65
7-250
HL
19
0.3
0.06
0.2
0.04-1
137
28.8
99
7-340
HIV-l-: HW seropositive patients: ASY: Asymptomatic HIV-t- patients: ARC: HIV-t- patients
with ARC symptoms: AIDS: HIV-f patients with AIDS symptoms: HL: HIV-t- patients with
hairy leukoplakia (HL).
was a significant difference or eorrela-
tion between the immunoeytoehemical
results gained from patients of different
clinical groups a parameter free test (U-
test Mann-Whitney) was used. Spear-
mann's correlation test was applied to
determine relations between the immu-
nocytochemical results and the clinical
and immunologie data.
Results
Clinical results
Nineteen healthy HIV-control persons
(average age: 33 years; men « = 9,
women ;?=10) were included in the
study. HIV-l- patients (men: « = 35,
women: « = 4; average age: 34.9 yr) were
in different risk groups for aequiring
HIV-infection: homo- or bisexual males
(28/39), i.v. drug users (9/39; men: n =
6, women: « = 3), hemophiliac (1/39)
and heterosexual women (1/39). The
patients were in different clinical stages
of HIV-infection: 6 patients were
asymptomatic, 12 patients showed ARC
symptoms (CDCIII/IVA) and 21 pa-
tients suffered from AIDS manifesta-
tions (CDC IV B-E).
During the observation time of 8
months in 7 patients progression of
HIV-associated disease was noted,
while 11/21 patients with AIDS mani-
festations died.
In all HIV+ patients the CD4/CD8
ratio was deereased (average: 0.3; range:
0.04-1.0), while in 60% the absolute
number of CD4 cells was below 100/^1
(average: 195/|il; range: 7-744/|il)
(Table 1). All patients with a CD4/CD8
ratio >0.1 and/or an absolute number
of CD4 cells <100/^I showed clinical
Fig. L Positive reactions in EBV infected Raji cells were located within nucleus, occasionally
within cytoplasm as well. APAAP x 200,
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Fig. 2. Positive reactions were found for EBV capsid and/or membrane antigens (A). Flattened (B) or polygonal (C) keratinocytes positive
for EBV revealed nuclear (D) and/or cytoplasmatic staining, but in addition cells morphologically not altered also stained positive (CS of
HIY+ patient. A: APAAP, x 300. B-C: APAAP, x400.
symptoms of AIDS tnanifestations. Be-
tween the elinieal stage of HIV-associ-
ated disease and the CD4/CD8 ratio
(Speannann-test: P = 0,03) as well as the
absolute number of CD4 positive eells
(Speannann-test: ^ = 0.03) significant
correlations were found.
Within the oral cavity clinical tnani-
festations of C. alhicans infection (26/
39), HSVl/2 assoeiated lesions (5/39),
Kaposi's sarcoma (8/39) and non-
Hodgkin's lymphoma (1/39) were ob-
served. In 19 patients (asymptomatic:
n = l; ARC: « = 7, AIDS: «=11) hairy
leukoplakia (HL) was clinically diag-
nosed at the lateral border of the ton-
gue. During the observation time of 8
months three more patients developed
this lesioti. There was a significant
correlation between the clinical finding
of HL and the progression of HIV-asso-
ciated disease (U-test Mann-Whitney:
P = 0.015). No correlation was found
between HL and the clinical stage of
HIV-associated disease, serologic im-
munoparameters (CD4/CD8 ratio, ab-
solute number of CD4 positive cells) or
the presence of other oral lesions.
At the titne of examination 15 pa-
tients received antiviral drugs: AZT
(Retrovir) ;;= 10. pentosan polysulfates
(HOE/BAY 946) n = 3, Ganeyclovir
(DHPG) n= 1; two patients were under
treatment with Acyclovir (Zovirax),
starting 2 days before exatnination. In
eight of these patients the clinical symp-
tom of HL was diagnosed; however,
antiviral medication showed no effect
on the clinical presentation of this
lesion.
immunocytochemical results:
EBV antigens - Using the APAAP tech-
nique Raji cells were negative for EBV,
while positive reactions were found in
EBV infected Raji cells (Fig. 1) and in
P3HR1 cells. Positive reaetions were
mainly located within the nucleus, in the
nucleus and cytoplasm and occasionally
only within the cytoplasm.
Table 2. Number of cases positive for EBV nuclear (NA), capsid (VCA) and early antigens
(EA) (APAAP) and for EBV DNA (in situ hybridization).
HIV-h
ASY
ARC
AIDS
HL
HL*
H L - / H L "
NA
18/39 (46%)
2/6 (33%)
9/12 (75%)
7/12 (33%)
13/19 (68%)
16/22 (73%)
* - 2/17 (12%)
EBV antigen
VCA
13/39 (33%)
3/6 (50%)
3/12 (25%0
7/12 (33%)
9/19 (47%)
11/22 (50%)
3/17 (18%)
EA
3/39 (8%)
0/6
2/12 (16%)
1/21 (5%)
1/19 (5%)
3/22 (14%)
0/17
H I V - 0/19 0/19 0/19
[Expression ol" more than one antigen/patient]
EBV antigen
total
24/39 (61%)
4/6 (55%)
9/12 (75%)
11/21 (52%)
16/19 (84%.)
19/22 (86%)
5/17 (29%)
0/19
EBV DNA
total
31/39
4/6
11/12
16/21
19/19
22/22
9/17
3/19
(79%)
(67'X,)
(92%)
(76%)
(100%,)
(100%)
(53%)
(17%)
HIV-)-: HIV seropositive (HIV + ) patients [n = 39]: ASY: Asymptomatic HIV+ patients [n-
6]: ARC: HIV-l- patients with ARC symptoms [n=12]: AIDS: HIV-l- patients with AIDS
symptoms [n = 21]: HL: HIV-H patients with hairy leukoplakia (HL) [n = 19]: HIV- : HIV
seroneeative persons [= 19]: HL*: HIV+ patients with HL or later development ofHL [n =
22]: H L - / H L * - : HIV-l- patients without HL or later development of HL [n = 17].
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While all cytologie cell preparations
(CS) from control persons were EB'V
negative, 24/39 (61%) CS of HIV+ pa-
tients were positive for EBV capsid
and/or membrane antigens (APAAP)
(Fig. 2A) (Table 2). Keratinocytes posi-
tive for EBV showed flattened (Fig, 2B)
or polygonal morphology (Fig. 2C) with
nuclear (Fig. 2D) and/or cytoplasmic
staining (Figs. 2B, C), in addition some
cells morphologically not altered
stained also positive.
While no correlation was found be-
tween the number of patients with posi-
tive results and the clinical stage of
HIV-assoeiated disease (Table 3), the
amount of positive cells/positive case
correlated with HIV-associated clinical
symptoms (Table 3) (Spearmann-test:
F= 0,001): in the group of asymptoma-
tic patients all positive eases were scored
as "-I-", while in the group of ARC
and AIDS patients most positive cases
showed more than 10 positive cells/slide
(Table 3), In the group of patients with
HL 16/19 patients (84%) revealed posi-
tive results for EBV-antigens. There
were significant correlations between
the clinical finding of HL and patients
with positive results for EBV antigen
(Spearmann-test: P = 0.001). Addition-
ally, correlations were found between
the presenee or development of HL and
the expression of certain EBV antigens
resp, the number of positive cells/case:
all patients showing positive results for
EA (ARC: n = 2, AIDS: «= 1) (Table 2)
or positive results scored as " -f -I-" or
" -t- -f -I-" for VCA (AIDS: n = 3) "and/
or NA (ARC: « = 5, AIDS: n = 5)
• • f"-'"
,^ ::^ -^i^ p^-
Eig. 3. On Ramos cells and P3HR1 cells positive reactions were not observed, while positive
staining was located within the nueleus and in cytoplasm of EBV infected Ramos cells (A)
ISH X 200 and of EBV infected P3HR1 cells (B) ISH x 400.
Eig. 4. EBV-DNA was found within nucleus and cytoplasm of celLs with intranuclear inclusions
and occasionally also in cells morphologically not altered. CS of HIV-f patient, ISH x 300.
showed the elinical symptom of HL (/; =
16) or developed HL during an observa-
tion time of 8 months (A! = 3) (Table 3).
Compared with 61% positive cases (24/
39) in the group of HIV-t- patients and
86% (19/22) in the group of patients
with presence or later development of
HL only five of 17 patients without HL
(29%) were EBV antigen positive (Table
2).
EBV-DNA - On Ramos eells and
P3HR1 cells positive reactions were not
observed, while positive staining was lo-
cated within the nucleus and in the cyto-
plasm of Raji cells, in EBV infected
Ramos and P3HR1 cells (Fig, 3A, B),
EBV-DNA was found within the nu-
eleus and the cytoplasm of cells with
intranuclear inclusions and occasionally
as well in cells morphologically not al-
tered (Fig. 4). 79% of CS (31/39) were
positive for EBV-DNA compared to 3/
19 HIV seronegative controls (Table 2).
While again the number of positive
cases in the different clinical stages var-
ied not significantly, a strong correla-
tion was found between the number of
positive cells/positive case and the clin-
ical classification of patients. While in
positive cases of HIV seronegative con-
trols (3/19) less than 5 cells were posi-
tive for EBV DNA, in the group of
HIV-f- patients the number of positive
cells/positive CS was mainly scored as
Eig. 5. While HEL cells were negalive for CMV struetural antigens, CMV infected HEL cells
showed positive reactions mainly within nucleus, occasionally within cytoplasm as well.
APAAP X 350, without counter staining.
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"+-t-" or "-f-l--|-". Cases scored as
" -f -f -I- " were not found in asymptom-
atic patients, but in 16% (2/12) of pa-
tients with ARC and in 28% (6/21) of pa-
tients with AIDS symptoms (Table 3).
There was a strong correlation be-
tween the oecurrenee of HL and positive
results for EBV-DNA and high num-
bers of positive cells/positive CS (Spear-
mann-test: P=0,0002): all CS scored as
" 4- -I- -I- " were taken from patients with
HL (n = 7) or who later on developed
HL {n= 1) (Table 3), All CS taken from
areas with the clinical diagnosis of HL
(19/19) atid from clinically uninvolved
areas in patients who developed HL
(n = 3) were positive for EBV-DNA
(Table 2),
CMV antigen - Positive staining for
CMV struetural antigens and for CMV
DNA was found within the nucleus and
the cytoplasm of cells with intranuclear
inclusions and occasionally as well in
eells morphologically not altered. While
HEL cells were negative for CMV struc-
tural antigens, CMV infected HEL cells
showed positive reactions mainly within
the nucleus and the cytoplasm (Fig. 5).
Using the APAAP technique in the
group of HIV-f patients 22/39 CS
(56%) were positive for CMV, while 2/
19 controls (11%) showed positive re-
sults as well (Table 4), Expression of
viral structural antigens was observed
within keratinocytes revealing enlarged
nuclei (Fig. 6A) and perinuclear halo
(Fig. 6B), mostly associated with cyto-
plasmic positive reactions.
While in the group of asymptomatic
HIV-f patients and in HlV-seronega-
tive controls less than 5 positive cells/
case were found, positive CS of ARC
and AIDS patients were mainly scored
as "-f -f " or "+ -I- -t-". No correlation
was found between the presence of HL
and positive results for CMV antigen
(Table 4).
CMV DNA - MRC-5 cells and HEL
cells were negative for CMV DNA,
while within the nucleus of CMV in-
fected MRC-5 cells (Fig. 7) and HEL
cells positive reaetions were observed.
By means of ISH 27/39 (69%) of HIV +
patients showed positive results for
CMV DNA (Fig. 8), while in 4/19
(21%) HIV seronegative controls posi-
tive results with less than 5 positive
cells/CS were found (Table 4). In the
different clinical stages the number of
patients with positive results for CMV
DNA was similar. Compared with
asymptomatic HIV-f patients ARC or
AIDS patients showed an increased
frequency of positive cases scored as
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Eig. 6. Positive staining for CMV structural antigens was found within nucleus and/or
cytoplasm of keratinoeytes revealing as signs of viral infection enlarged nuclei (A) with
perinuclear halo (arrow) (B). CS of HIV-f patient: A: APAAP, x450. B: APAAP, x 300.
"-f -f " or "-f -f -f " (Table 4). Positive
results for antigens/DNA of both
viruses were not correlated with the
medication of antiviral drugs («= 15 pa-
tients). However, one AIDS patient
under medication with Gancyclovir
(DGHP) (duration: 4 months prior
sampling) was negative for EBV and
CMV in both techniques, while 2 pa-
tients receiving Acyclovir (Zovirax) for
2 days before sampling revealed positive
results for viral antigens/DNA.
Discussion
The pathogenesis of AIDS may be influ-
enced by several cofactors (11, 12). Her-
pes viruses may be of special import-
ance, because they are ubiquitous, have
a particularly high prevalence in certain
high-risk populations and cause in-
creased morbidity and mortality in pa-
tients with AIDS, Herpes viruses are
characterized by three biologically and
clinically distinct features: latency after
initial infection and initial replication,
reactivation during alterations of the T-
cell mediated immunity, and potential
transformation of the host cell to a ma-
lignant state (13). Virus persistenee and
latent infection may occur due to dif-
ferent mechanisms: viruses may contin-
ue to replicate very slowly, eventually
producing disease due to cytoiytic infec-
tion. They may also cause chronic cyto-
iytic infection with continuous viral pro-
duction that does not cause disease,
such as persistant asymptomatic shed-
ding of CMV in urine or EBV and HSV
in saliva. Virus replication and subclini-
cal shedding may also be intermittent
without producing lesions (14), In each
of these cases the infection is subelinieal
either because dying host cells are re-
plaeed rapidly in the tissues or because
the host has little or no inflammatory
response (13-15).
There is ample evidence of EBV infec-
tion in patients with AIDS (16, 17); ti-
ters of EBV-related antibodies as well
as numbers of EBV-infected cells in the
peripheral blood of HIV-infected pa-
tients are higher than those in HI V-sero-
negative healthy persons (17). While
human B lymphocytes are the usual
target, EBV can also infect and replicate
in epithelial cells of oropharyngeal and
genital sites (18-21). The receptor for
EBV, which corresponds to the comple-
ment fraction 3rd receptor (C3), has
been identified on B-cells, certain T cells
(22) and on keratinocytes of the middle
and upper spinous layer of parakeratin-
ized epithelium (23). In HL epithelial
cells with this plasma membrane recep-
tor are known as the site of replieating
virus (23),
In the present study 61% (APAAP)
resp. 79% (ISH) of oral CS gained from
HIV-infected patients contained kerati-
nocytes positive for EBV. Similar results
were gained using electronmieroscopy
(negative staining technique), where
53% of HIV-infected patients showed
positive results (unpublished), using in
situ hybridization, where EBV expres-
sion was found in up to 76% of homo-
sexual men (24) or by cytospin in situ
hybridization technique in 23/25 cases
of HL (25), As deseribed in other studies
(12, 27) positive staining was detected
in cells with and without phenotypic evi-
dence of viral infection.
Excretion of EBV has been stated as
sensitive marker of underlying immuno-
deficiency. In HIV-infected patients
high levels of EBV excretions correlated
with a high probability of HlV-progres-
sion, prior to significant changes in
CD4/CD8 ratios (24), while Alsip and
coworkers found higher levels of EBV
excretion in AIDS patients than in pa-
tients with ARC symptoms or with
acute infeetious mononucleosis (27).
Similar results were found in the present
study, where the amount of positive
eells/positive ease correlated with the
stage of HIV associated disease: the
highest percentage of positive CS/posi-
tive case was found in the group of pa-
tients with ARC and AIDS manifesta-
tions, suggesting that these patients
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Table 4. Number of cells positive for CMV antigen/positive case (APAAP) and for CMV DNA/positive case (in situ hybridisation).
Seore
HIV-f
ASY
ARC
AIDS
HL
HIV-
14/39
3/6
4/12
3/21
10/19
2/19
-f
(36%)
(50%)
(33%)
(14%)
(53%)
(11%)
-f
7/39
0/6
5/12
6/21
2/19
0/19
CMV
-f
(18%)
(42%)
(29%)
(10%)
antigen
-f-f-f
1/39 (3%)
0/6
0/12
1/21 (5%)
0/19
0/19
total
22/39 (56%)
3/6 (50%)
9/12 (75%)
10/21 (48%)
12/19 (63%)
2/19 (lr/o)
16/39
4/6
4/12
4/21
9/19
4/19
-f
(41%)
(67%)
(33%)
(19%)
(47%)
(21%)
-f
9/39
1/6
5/12
7/21
1/19
0/19
CMV
-f
(23%)
(17%)
(42%)
(33%)
(5%)
DNA
-f
2/39
0/6
0/12
2/21
2/19
0/19
-f-f
(5%)
(10%)
(11%)
total
27/39 (69%)
5/6 (83%)
9/12 (75%)
13/21 (61%)
12/19 (63%)
4/19 (21%)
Score -f: < 5 positive cells/slide; Score -f -f: 5 to 10 positive cells/slide; Score -f -f-f: <10 positive cells/slide.
HIV-f: HIV seropositive (HIV-f) patients [n = 39]; ASY: Asymptomatic HIV-f patients [n = 6]; ARC: HIV-f patients with ARC symptoms
[n=12]; AIDS: HIV-f patients with AIDS symptoms [n = 21]; HL: HIV-f patients with hairy leukoplakia (HL) [n=19]; H I V - : HIV
seronegative control persons [n= 19].
have an altered immunoregulation of
EBV
In contrast, positive results in HIV-
seronegative persons examined in the
present study have been a very rare find-
ing and positive cases (3/19) revealed a
very low number of positive cells. Sim-
ilar results were described by ALSIP et
al. (27) while others found low as well
as oeeasionally high excretion of EBV
in the general population (13, 14, 16).
This may occur due to asymptomatic
shedding, which has been demonstrated
in up to 60% of healthy adults or due
to immunosuppression caused by other
factors than HIV-infection (16).
Apart from the clinical stage the posi-
tive results for EBV correlated with the
clinieal diagnosis of HL, and seemed
even to preeeede the clinical tnanifesta-
tion of HL in three patients: all patients
revealing positive results for EA or posi-
tive results for VCA or NA with high
numbers of positive cells/case showed
the presence or later development of
HL, This lesion is a frequent and early
clinical symptom pointing to an under-
lying immunodeficiency. It was first
described in HIV infeeted homosexual
men, later as well in all other groups at
risk for HIV-infection (3, 4), HL has
been considered to be a highly predic-
tive lesion for the development of AIDS
(28), a fact which has also been stated
in the present study. The correlation be-
tween the clinical finding or later devel-
opment of HL with the progression of
HIV-associated disease may be reflected
in the imtnunoeytoehemical results for
EBV: while 61% of HIV-I- patients and
84% of HIV-f patients with HL showed
positive results for EBV, only five of 17
patients without presence or later devel-
opment of HL were EBV antigen posi-
tive. Sinee the clinical diagnosis of HL
may have further consequences for the
individual patient, it has been pos-
tulated that for eonfirmation biochemi-
eal proof of EBV would be necessary
(5). The examination of oral CS, de-
seribed in this study, offers the possi-
bility of gaining samples from a relative-
ly large area by means of a non-invasive
technique. The diagnostic accuracy is
comparable with results gained by biop-
sies (4, 5),
The increased load of EBV found in
the oral CS of our patients may have
various consequences: since EBV itself
is an effective unspecific immunostimu-
lant it may trigger the progression of the
disease by activation of CD4"^  epithelial
cells and thereby coactivating latent
HIV which leads to destruction of these
cells (17, 29), The decreasing number of
CD4 eells rnay in turn favor further B-
cells already latently infected by EBV
to complete a full lytic cycle of viral
replication without prior immunoelimi-
nation. Whether the increased finding
of oral lymphomas in HIV-infected pa-
tients may be related to the inereased
EBV expression (30), is yet unknown,
but may well relate to similar mecha-
nisms,
CMV can be transmitted via saliva as
well as through blood and sexual con-
tact (16), After the initial replication in
epithelial cells CMV takes up long-term
residence in circulating leukocytes.
#
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Eig. 7. MRC-5 cells were negative for CMV DNA, while within nucleus of CMV infected
MRC-5 cells positive reactions were observed. ISH x 200.
Eig. 8. Mainly intranuclear CMV DNA was
detected in 69% of CS of HIV-f patients. CS
of HIV-f patient. ISH x 300.
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More than 50% of healthy adults and
almost 100% of HIV positive homosex-
uals have serum antibodies to CMV
(31). CMV has been isolated from the
pharynx in 74% (32) and from parotid
saliva in more than 65% of patients with
AIDS (33). The examination of oral CS
in the present study showed comparable
results: 56% (APAAP) resp. 69% (ISH)
of CS from HIV-infected patients
showed positive results for CMV anti-
gen resp. CMV DNA, while in control
CS 11% resp. 21% were positive for
CMV antigen resp. CMV DNA. In ad-
dition to detection of CMV antigen/
DNA within cytomegalie cells, positive
results were found also in the nucleus
and cytoplasm of cells without enlarge-
ment or inclusion formation. Similar
findings have been described by others
in various tissues (34-36).
In contrast to their protective func-
tion, elevated serum titers of CMV anti-
bodies seem to be a significant predictor
for the development of AIDS (31).
While symptomatie infection with CMV
occurs very rarely in healthy adults,
CMV is a critical opportunistic patho-
gen in the immunocompromised host
(31). Whether the enhancement oflocal
CMV replieation correlates with in-
creasing levels of CMV viremia during
the progression from ARC to AIDS
symptoms and CMV involvement of
various organs is under investigation.
For both viruses comparatively low
numbers of positive results were found
in the group of AIDS patients exam-
ined in the present study. This may
partly be due to CS of four patients
with AIDS symptoms, in which
antigens/DNA of EBV and CMV were
not detected. In one of these patients
treatment with DHPG for a period of
4 months before sampling may be the
reason for negative results. The re-
maining three patients received ACT,
were under different antibacterial and
antifungal therapies and died shortly
after the oral samples were taken. Re-
sults in these patients may refleet coin-
cidental changes of viral shedding, may
result from prolonged multiple thera-
pies or may be eonnected with the im-
munoregulatory breakdown of the late
stage of HIV-associated disease.
The oral mucosa allows diagnostic
procedures with easy aecessibility. The
examination of cytologic smears of the
oral mucosa provides the benefit of be-
ing non-invasive, of gaining material
from a relatively large surface compared
to biopsy, and of repeated sampling of
the same patient during clinical follow-
up. However, due to the presenee of cell
detritus, mucus, bacterial and fungal
micro-organisms adhering to the epi-
thelial cells the cytospin technique, used
in a prestudy, had resulted in an unequal
distribution of epithelial cells. Due to a
different technique, which was devel-
oped to gain cytologic cell preparations
with single cell suspension, the examina-
tion of single epithelial cells was pos-
sible. In further prospective studies it
will be evaluated whether serial sam-
plings of oral CS taken from the same
patient can facilitate assessments of the
effects of antiviral therapies and give
insight into the possible role of these
viruses in HIV-associated disease.
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